Cetyl Myristoleate (CMO) was discovered and isolated by Harry W. Diehl, while employed by the National Institute of Arthritis, Metabolism and Digestive Diseases. Diehl was awarded a use patent for its use for rheumatoid arthritis in 1977.

The exact mechanism of cetyl myristoleate’s physiologic activity is unclear.

It appears to have the same characteristics as the essential fatty acids, linoleic and alpha linolenic acids, except stronger and longer lasting.   These fatty acids are referred to as “essential fatty acids” because the human body cannot make them and must be ingested as part of the foods that are consumed.

EFA’s are essential to normal cell structure and body function and as components of nerve cells, cell membranes, and hormone-like substances known as prostaglandins.

Cetyl Myristoleate is reported to support the body’s ability to lubricate joints and muscles, maintain and promote connective tissues and promote flexibility.

Cetyl Myristoleate is also reported to support the body’s ability to manage immune system and inflammation responses.